# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k053653   
B. Purpose for Submission: This is a new device.   
C. Measurands: Anti-SS-A, anti-SS-B, anti-Sm, anti-Sm/RNP, anti-dsDNA, anti-Scl-70, anti-Jo1, ribosome and centromere   
D. Type of Test: Multiplex bead-based flow cytometric immunoassay   
E. Applicant: Biomedical Diagnostics (bmd) S.A.   
F. Proprietary and Established Names: FIDIS™ Connective $1 0 ^ { * }$

# G. Regulatory Information:

1. Regulation section: 21CFR§ 866.5100, Antinuclear Antibody Immunological Test System   
2. Classification: Class II   
1. Product code: LLL, Extractable Antinuclear Antibody, Antigen, and Control LKJ, Antinuclear Antibody, Antigen, Control LKO, Anti-RNP Antibody, Antigen, Control LKP, Anti-Sm Antibody, Antigen, and Control LSW, Anti-DNA Antibody, Antigen and Control LJM, Antinuclear Antibody (Enzyme Labeled), Antigen, Controls MQA, Anti-Ribosomal P Antibodies

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): The FIDIS ™ Connective $1 0 ^ { * }$ kit is a fluorescent immunoassay for the semiquantitative simultaneous detection of 10 autoantibody specificities directed against double stranded DNA (dsDNA), SSA ( $6 0 \mathrm { k D A }$ and $5 2 \mathrm { k D A }$ ), SSB, Sm, Sm/RNP, Scl-70, Jo-1 ribosome and centromere in human serum. (\*Antibodies to dsDNA, SSA, SSB, Sm, Sm/RNP, Scl-70, Jo-1, ribosome and centromere can be reported using this assay).

2. Indication(s) for use:

The FIDIS ™ Connective $1 0 ^ { * }$ kit is a semi-quantitative homogeneous fluorescent based microparticles immunoassay using flow cytometry readings. It is designed for the simultaneous detection of autoantibody specificities: double stranded DNA (dsDNA), SSA ( $6 0 \mathrm { k D A }$ and $5 2 \mathrm { k D A }$ ), SSB, Sm, Sm/RNP, Scl-70, Jo-1 ribosome and centromere in human serum. (\*Antibodies to dsDNA, SSA, SSB, Sm, Sm/RNP, Scl-70, Jo-1 ribosome and centromere can be reported using this assay).

The test system is used to screen serum samples and detect the presence of antinuclear antibodies associated with connective diseases systemic lupus erythematosus (SLE), Sjogren’s syndrome, mixed connective tissue disease (MCTD), scleroderma, dermatomyositis, and CREST syndrome, in conjunction with clinical findings and other laboratory tests.

3. Special conditions for use statement(s): This device is for prescription use only.

4. Special instrument requirements: FIDIS™ Instrument (Luminex $\overline { { 1 0 0 } } ^ { \mathrm { T M } }$ plus FIDIS™ MLX-Booster Software) CARIS™ (Optional diluting and dispensing device)

# I. Device Description:

The device consists of the following: color-coded sets of microspheres (ready-to-use). Each microsphere set is conjugated to one of the following antigens: dsDNA, SSa (60 kDA and $5 2 \mathrm { k D A }$ ), SSB, Sm, Sm/RNP, Scl-70, Jo-1, ribosome and centromere; calibrator (ready to use); positive control (to be diluted); negative control (to be diluted); goat anti-human IgG conjugate coupled phycoerythrin (to be diluted) and $1 0 \mathrm { x }$ concentrated PBS-Tween (to be diluted with distilled water)

# J. Substantial Equivalence Information:

1. Predicate device name(s): Varelisa LA (SS-B) Antibodies, Varelisa RO (SS-A) Antibodies, Varelisa Jo-1 Antibodies, Varelisa Sm Antibodies, Varelisa RNP Antibodies, Varelisa dsDNA Antibodies, Varelisa Scl-70 Antibodies, Varelisa Centromere Antibodies, and QuantaLite Ribosome P ELISA.   
2. Predicate 510(k) number(s): k944168, k944169, k944173, k944170, k993589, k950031, k944172, k944171 and k981237.

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>FIDISTM Connective 10*</td><td rowspan=1 colspan=1>Individual Varelisa ELISA assaysfor autoantibodies to LA (SS-B),RO (SS-A), Jo-1, Sm, RNP, dsDNAScL-70, Centromere andQuantaLite Ribosome P</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Individual determination of IgGantibodies to dsDNA,SSA 60 kDA and 52 kDA, SSB,Sm/RNP, ScL-70, Jo-1,ribosome and centromere</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of test</td><td rowspan=1 colspan=1>Semi-quantitative</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Assay type</td><td colspan="1" rowspan="1">Flow Cytometer based</td><td colspan="1" rowspan="1">ELISA</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Multiplexed</td><td colspan="1" rowspan="1">Individual analytes</td></tr><tr><td colspan="1" rowspan="1">Sample Dilution</td><td colspan="1" rowspan="1">1:200</td><td colspan="1" rowspan="1">1:101</td></tr><tr><td colspan="1" rowspan="1">Substrate solution</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">TMB</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Luminometer (Luminex2.2)</td><td colspan="1" rowspan="1">Spectrophotometer</td></tr><tr><td colspan="1" rowspan="1">Detection method</td><td colspan="1" rowspan="1">Fluorescence</td><td colspan="1" rowspan="1">Colorimetric</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Phycoerythrin</td><td colspan="1" rowspan="1">HR peroxidase</td></tr><tr><td colspan="1" rowspan="1">Solid Phase Capture</td><td colspan="1" rowspan="1">Color-coded microsphere</td><td colspan="1" rowspan="1">Microwells</td></tr><tr><td colspan="1" rowspan="1">Antigens</td><td colspan="1" rowspan="1">Recombinant dsDNA,SSA,SSB, Scl70, Jo1,and Centromere; PurifiedSm, Sm/RNP andRibosome P</td><td colspan="1" rowspan="1">Recombinant dsDNA,SSA, SSB, Scl70, Jo1,RNP, and Centromere;Synthetic SmD peptide,And Ribosome P</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None referenced.

# L. Test Principle:

FIDIS™ Connective $1 0 ^ { * }$ is a multiplexed semi-quantitative, fluorescent immunoassay performed on the FIDIS ™ Instrument (Luminex $1 0 0 ^ { \mathrm { T M } } )$ with the MLX Booster software. Each antigen (dsDNA, SSA $[ 6 0 \mathrm { k D A }$ and $5 2 \mathrm { k D A } ]$ , SSB, Sm, Sm/RNP, Scl-70, Jo-1, ribosome and centromere) is covalently coupled to an individual set of microspheres through its surface functional groups. The different sets of antigen-coupled microspheres are mixed together to constitute the final microspheres reagent and put into wells of a microtiter plate. Prediluted controls and diluted patient sera are added to separate wells allowing autoantibodies to bind to the immobilized antigens on the beads. After incubation, a wash step through a filtration process will remove the unbound antibodies. Then a phycoerythrin labeled antihuman $\mathrm { I g G }$ is added to each well and binds to any patient autoantibodies/antigen complexes on the microspheres. The samples are subsequently measured in the FIDIS Instrument. The flow cytometer discriminates the different bead sets as well as measures the fluorescent intensity of the conjugate on each bead. For each sample, the antibody titer for each antigenic specificity is interpolated against a calibration system.

FIDIS™ Connective $1 0 ^ { * }$ was optimized by flow cytometry for the average binding capacity at the given dilution (1:200) from the median fluorescence value using 200 microspheres per parameter.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: To evaluate intra-assay and inter assay reproducibility, five samples covering the reportable range of the assay were analyzed on the FIDIS™ Connective $1 0 ^ { * }$ . For within-run, the five samples were assayed 10 times in one run and for between-run; the three samples were assayed 2 times per run for 6 runs. Results were as follows:

<table><tr><td colspan="3">Within-run</td><td colspan="2">Between-run</td></tr><tr><td>Antigenic Specificity</td><td>Mean value</td><td>%CV</td><td>Mean Value</td><td>%CV</td></tr><tr><td rowspan="4">dsDNA</td><td>45 55</td><td>6.0 2.5</td><td>48 49</td><td>14.0 6.6</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>71</td><td>5.0</td><td>67</td><td>8.0</td></tr><tr><td>105 687</td><td>6.1</td><td>102</td><td>7.4 5.1</td></tr><tr><td rowspan="6">SSA 60 kDA / SSA52kDA</td><td>28</td><td>2.6 11.0</td><td>667 27</td><td>9.0</td></tr><tr><td>50</td><td>12.0</td><td>46</td><td>13.0</td></tr><tr><td></td><td></td><td></td><td>8.5</td></tr><tr><td>66</td><td>13.8</td><td>52</td><td></td></tr><tr><td>81</td><td>3.5</td><td>76</td><td>3.9</td></tr><tr><td>248 46</td><td>3.6</td><td>241</td><td>4.9</td></tr><tr><td rowspan="4">SSB</td><td>54</td><td>8.0 6.0</td><td>41 53</td><td>11.0 10.0</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>56</td><td>6.7</td><td>45</td><td>7.5</td></tr><tr><td>80 131</td><td>3.1 2.5</td><td>73 122</td><td>9.1 6.2</td></tr><tr><td rowspan="4">Sm</td><td>25</td><td>11.0</td><td>26</td><td>11.0</td></tr><tr><td>28</td><td>9.0</td><td>29</td><td>8.0</td></tr><tr><td>45</td><td>9.7</td><td>35</td><td>7.1</td></tr><tr><td>90</td><td>4.0</td><td>87</td><td>6.4</td></tr><tr><td rowspan="4">Sm/RNP</td><td>115</td><td>2.5</td><td>134</td><td>6.7</td></tr><tr><td>20</td><td>10.0</td><td>31</td><td>10.0</td></tr><tr><td>44</td><td>5.5</td><td>55</td><td>8.9</td></tr><tr><td>67 89</td><td>4.0</td><td>63</td><td>9.0</td></tr><tr><td rowspan="4">Scl-70</td><td>110</td><td>3.1 2.6</td><td>88 114</td><td>4.6 7.1</td></tr><tr><td>28</td><td>9.0</td><td>30</td><td>14.0</td></tr><tr><td>34</td><td></td><td></td><td>14.0</td></tr><tr><td>49</td><td>15.0 10.9</td><td>35 76</td><td>8.8</td></tr><tr><td rowspan="4">Jo-1</td><td>97</td><td>8.4</td><td>84</td><td>5.8</td></tr><tr><td>180</td><td>3.5</td><td>152</td><td>8.5</td></tr><tr><td>50</td><td></td><td></td><td></td></tr><tr><td>60</td><td>8.0 8.0</td><td>59 59</td><td>9.0 9.0</td></tr><tr><td rowspan="4"></td><td>91</td><td>7.0</td><td>79</td><td>4.7</td></tr><tr><td>176</td><td>6.2</td><td>170</td><td>7.8</td></tr><tr><td>285</td><td></td><td>266</td><td>8.8</td></tr><tr><td>30</td><td>2.1 8.0</td><td>27</td><td>12.0</td></tr><tr><td rowspan="4">Centromere</td><td>54</td><td>4.2</td><td>44</td><td>6.3</td></tr><tr><td>94</td><td>3.3</td><td>82</td><td>7.3</td></tr><tr><td>97</td><td>7.0</td><td>88</td><td>9.0</td></tr><tr><td>181</td><td>2.1</td><td>156</td><td>7.3</td></tr><tr><td rowspan="5">Ribosome</td><td>51 68</td><td>5.0</td><td>49</td><td>8.0</td></tr><tr><td></td><td>3.0</td><td>52</td><td>8.6</td></tr><tr><td>69</td><td>7.0</td><td>64</td><td>11.0</td></tr><tr><td>87</td><td></td><td></td><td></td></tr><tr><td>136</td><td>2.0 2.5</td><td>79 132</td><td>8.5 5.5</td></tr></table>

Precision of the assay using the optional automated CARIS system was assessed. For within-run, seven samples were assayed 10 times in one run and for betweenrun; seven samples were assayed 4 times per run for 6 runs. Three antigens were chosen for this study. Results were as follows:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Between-run</td></tr><tr><td rowspan=1 colspan=1>AntigenicSpecificity</td><td rowspan=1 colspan=1>Meanvalue</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>MeanValue</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>37077</td><td rowspan=1 colspan=1>6.012.0</td><td rowspan=1 colspan=1>36073</td><td rowspan=1 colspan=1>611.0</td></tr><tr><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>193</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>187</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=2 colspan=1>SSA 60 kDASSA52kDA</td><td rowspan=2 colspan=1>150705612</td><td rowspan=2 colspan=1>6.55.08.08.0</td><td rowspan=1 colspan=1>1496953</td><td rowspan=1 colspan=1>9.04.014.0</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>10.0</td></tr></table>

b. Linearity/assay reportable range:

Linearity is not claimed for this assay.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The dsDNA values in the calibrator are established using the WHO International Standard for anti-double stranded DNA (dsDNA), human code: WO/80. Other calibrator titers are expressed in arbitrary units per mL (AU/mL).

d. Detection limit: Not applicable e. Analytical specificity: Interfering substances

To evaluate the system for potential cross reactivity to other antibodies and interference from blood components, 52 samples were tested. High level of complement proteins were used but the specific kind of complement was not provided. A statement to avoid the use of abnormal concentration of these samples was added to the Limitations of the Procedure. The following results were obtained:

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=9>Number of Positive Samples</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>SSA60 &amp;52kD</td><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>Sm</td><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>Jo1</td><td rowspan=1 colspan=1>Centromere</td><td rowspan=1 colspan=1>Ribosome</td></tr><tr><td rowspan=1 colspan=1>Cryoglobulinemia (6)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Complement (8)</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Hypergammaglobulinemia(11)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>IgG monoclonal Ig (3)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>IgM monoclonal Ig (8)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (8)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Blood Plasma (6)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Hemolyzed sera (6)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Citrated Plasma (6)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: The tables below show the comparison of serum samples $\scriptstyle ( \mathrm { N } = 4 3 4$ ) that were tested with the FIDIS™ Connective $1 0 ^ { * }$ and the predicate devices. No information about age, gender, and clinical status was provided.

307 positive samples for one or more parameters related to systemic autoimmune diseases 227 negative samples All borderline results with the two devices were considered negative.

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa dsDNA</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISdsDNA</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>365</td></tr></table>

Positive $\%$ agreement: $9 5 . 0 8 \%$ $9 5 \%$ CI: $8 9 . 7 \% - 1 0 0 \%$ Negative $\%$ agreement: $9 7 . 8 6 \%$ $9 5 \%$ CI: $9 6 . 4 \% \mathrm { n } \mathrm { - } 9 9 . 3 \% )$ Overall $\%$ agreement: $9 7 . 4 7 \%$ $9 5 \%$ CI: $9 6 . 0 \% - 9 8 . 9 \% )$

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa SS-A</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISSS-A</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>283</td></tr></table>

Positive $\%$ agreement: $9 3 . 5 5 \%$ $9 5 \%$ CI: $8 9 . 2 \% - 9 7 . 9 \% )$ Negative $\%$ agreement: $9 0 . 4 2 \%$ $9 5 \%$ CI: $8 7 . 2 \% - 9 3 . 7 \% )$ Overall $\%$ agreement: $9 1 . 3 0 \%$ $9 5 \%$ CI: $8 8 . 7 \% - 9 3 . 9 \% )$

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa SS-B</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISSS-B</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>363</td></tr></table>

Positive $\%$ agreement: $9 4 . 2 3 \%$ $9 5 \%$ CI: $8 7 . 9 \%$ , $- 1 0 0 . 0 \%$ ) Negative $\%$ agreement: $9 5 . 0 3 \%$ $9 5 \%$ CI: $9 2 . 8 - 9 7 . 2 \%$ Overall $\%$ agreement: $9 4 . 9 3 \%$ $9 5 \%$ CI: 92.9% -97.0%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa Sm</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISSm</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>365</td></tr></table>

Positive $\%$ agreement: $9 1 . 0 7 \%$ $9 5 \%$ CI: $8 3 . 6 \% - 9 8 . 5 \% )$ Negative $\%$ agreement: $9 6 . 5 6 \%$ $9 5 \% \mathrm { C I }$ : 94.1% - 98.4%) Overall $\%$ agreement: $9 5 . 8 5 \%$ $9 5 \%$ CI: 94.0% - 97.7%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa Sm/RNP</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISSm/RNP</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>318</td></tr></table>

Positive $\%$ agreement: $8 5 . 7 1 \%$ $9 5 \%$ CI: $7 8 . 8 \% - 9 2 . 6 \% )$

Negative $\%$ agreement: $9 4 . 6 4 \%$ $9 5 \% \mathrm { C I }$ : 92.2% - 97.1%) Overall $\%$ agreement: $9 2 . 6 3 \%$ $9 5 \%$ CI: 90.2%- 95.1%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa Scl70</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISScl-70</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>385</td></tr></table>

Positive $\%$ agreement: $9 4 . 1 2 \%$ $9 5 \%$ CI: $8 6 . 2 \% - 1 0 0 \%$ ) Negative $\%$ agreement: $9 8 . 7 5 \%$ $9 5 \% \mathrm { C I }$ : 97.7% - 99.8%) Overall $\%$ agreement: $9 8 . 4 \%$ $9 5 \%$ CI: 97.2% - 99.6%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Varelisa Jo1</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISJo-1</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>392</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $9 8 . 0 0 \%$ $9 5 \% \mathrm { C I }$ : $9 6 . 6 \% - 9 9 . 4 \% )$ Overall $\%$ agreement: $9 8 . 1 6 \%$ $9 5 \%$ CI: $9 6 . 9 \% - 9 9 . 4 \% )$

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>VarelisaCentromere</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISCentromere</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>383</td></tr></table>

Positive $\%$ agreement: $9 5 . 7 4 \%$ $9 5 \% C \mathrm { I }$ : $9 0 . 0 \% - 1 0 0 . 0 \%$ Negative $\%$ agreement: $9 8 . 9 7 \%$ $9 5 \% \mathrm { C I }$ : $9 8 . 0 \% - 1 0 0 . 0 \% )$ Overall $\%$ agreement: $9 8 . 6 2 \%$ $9 5 \%$ CI: $9 7 . 5 \% - 9 9 . 7 \% )$

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>QuantaLiteRibosome</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>FIDISRibosome</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>404</td></tr></table>

Positive $\%$ agreement: $9 2 . 3 1 \%$ $9 5 \% \mathrm { C I }$ : $8 2 . 1 \% - 1 0 0 . 0 \% )$ Negative $\%$ agreement: $9 9 . 0 2 \%$ $9 5 \% \mathrm { C I }$ : $9 8 . 1 \% - 1 0 0 . 0 \% )$ Overall $\%$ agreement: $9 8 . 6 2 \%$ $9 5 \%$ CI: $9 7 . 5 \% - 9 9 . 7 \% )$

Comparison of the automated CARIS system and manual method A comparison study between the manual method and the automated CARIS™ system was also performed. The comparison was performed on 36 samples. All borderline results with the two methods were considered negative.

<table><tr><td rowspan=2 colspan=2>SSA (60kD+52kD)</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CARISFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>17</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $9 4 . 4 \%$ Overall $\%$ agreement: $9 7 . 2 \%$

<table><tr><td rowspan=2 colspan=2>SSB</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>31</td></tr></table>

Positive $\%$ agreement: $8 0 . 0 \%$ Negative $\%$ agreement: $1 0 0 . 0 \%$ Overall $\%$ agreement: 97.2%

<table><tr><td rowspan=2 colspan=2>Sm</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>Sm/RNP</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>Scl70</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>32</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $1 0 0 . 0 \%$ Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>Jo1</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>31</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $1 0 0 . 0 \%$ Overall $\%$ agreement: $1 0 0 . 0 \%$

<table><tr><td rowspan=2 colspan=2>Centromere</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>Ribosome</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>dsDNA</td><td rowspan=1 colspan=2>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $1 0 0 . 0 \%$ Overall $\%$ agreement: $1 0 0 . 0 \%$ b. Matrix comparison: Serum is the only recommended matrix.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The reported expected ranges were estimated from 2 populations:

• 50 samples from blood donors 48 samples selected from their potential biological interferences and according to WHO standard for dsDNA specificity

<table><tr><td rowspan=1 colspan=1>Arbitrary units (AU/mL)</td><td rowspan=1 colspan=1>&lt;30AU/mL</td><td rowspan=1 colspan=1>30-40AU/mL</td><td rowspan=1 colspan=1>&gt;40AU/mL</td></tr><tr><td rowspan=1 colspan=1>International units (IU/mL)For dsDNA</td><td rowspan=1 colspan=1>&lt;30IU/mL</td><td rowspan=1 colspan=1>30-40IU/mL</td><td rowspan=1 colspan=1>&gt;40IU/mL</td></tr><tr><td rowspan=1 colspan=1>Interpretation</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Positive</td></tr></table>

The negative thresholds $( 3 0 \mathrm { A U / m L }$ or $3 0 \mathrm { I U / m L }$ ) correspond to the $9 7 . 9 ^ { \mathrm { t h } }$ percentile for dsDNA, SSA, $\operatorname { S m } / \operatorname { R N P }$ ; $9 9 . 0 \%$ for centromere and ribosome, and $100 \%$ for SSB, Sm, Scl70 and Jo1 for the populations studied.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.